secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001104659-25-029654
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics: second IDMC review finds VCN-01 well tolerated in metastatic PDAC trial
--------------------------------------------------------------------------------

- IDMC reviewed safety data from 101 patients across 14 sites in US and Spain.
- VCN-01 AE profile consistent with prior trials; AEs transient and reversible, less frequent after second dose.
- Patient enrollment completed Sep 2024; topline clinical outcomes data expected Q2 2025.
- CEO says positive data, along with prior FDA/EMA feedback, could guide Phase 3 registrational trial design.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465925029654/0001104659-25-029654-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465925029654/tm2510883d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-029654

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer